This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesTrendsBuy This Stock TALS vs. ALVO, IMVT, IBRX, RXRX, TWST, DNLI, VCEL, BEAM, TARS, and KYMRShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Alvotech (ALVO), Immunovant (IMVT), ImmunityBio (IBRX), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Vericel (VCEL), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry. Talaris Therapeutics vs. Alvotech Immunovant ImmunityBio Recursion Pharmaceuticals Twist Bioscience Denali Therapeutics Vericel Beam Therapeutics Tarsus Pharmaceuticals Kymera Therapeutics Talaris Therapeutics (NASDAQ:TALS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Which has stronger earnings and valuation, TALS or ALVO? Talaris Therapeutics has higher earnings, but lower revenue than Alvotech. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalaris TherapeuticsN/AN/A-$73.89M-$1.79-9.97Alvotech$489.68M4.89-$551.73M-$0.87-9.13 Is TALS or ALVO more profitable? Talaris Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Talaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Talaris TherapeuticsN/A -39.93% -37.37% Alvotech -123.47%N/A -35.87% Which has more volatility and risk, TALS or ALVO? Talaris Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Does the MarketBeat Community favor TALS or ALVO? Talaris Therapeutics received 6 more outperform votes than Alvotech when rated by MarketBeat users. However, 50.00% of users gave Alvotech an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote. CompanyUnderperformOutperformTalaris TherapeuticsOutperform Votes1348.15% Underperform Votes1451.85% AlvotechOutperform Votes750.00% Underperform Votes750.00% Does the media favor TALS or ALVO? In the previous week, Alvotech had 4 more articles in the media than Talaris Therapeutics. MarketBeat recorded 4 mentions for Alvotech and 0 mentions for Talaris Therapeutics. Talaris Therapeutics' average media sentiment score of 0.00 beat Alvotech's score of -0.09 indicating that Talaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Talaris Therapeutics Neutral Alvotech Neutral Do analysts rate TALS or ALVO? Alvotech has a consensus target price of $18.00, suggesting a potential upside of 126.70%. Given Alvotech's stronger consensus rating and higher possible upside, analysts clearly believe Alvotech is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in TALS or ALVO? 67.6% of Talaris Therapeutics shares are owned by institutional investors. 16.5% of Talaris Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryAlvotech beats Talaris Therapeutics on 10 of the 17 factors compared between the two stocks. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$763.34M$2.95B$5.54B$7.93BDividend YieldN/A1.89%5.09%4.23%P/E Ratio-9.9730.0722.5318.54Price / SalesN/A494.82399.57103.29Price / CashN/A168.6838.1834.62Price / Book4.123.176.774.25Net Income-$73.89M-$72.35M$3.22B$248.18M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$17.85+3.7%N/A+9.5%$763.34MN/A-9.9784ALVOAlvotech1.7395 of 5 stars$8.36+0.4%$18.00+115.3%-45.2%$2.52B$489.68M-4.524Short Interest ↑News CoverageIMVTImmunovant2.2217 of 5 stars$14.25-1.5%$38.33+169.0%-44.2%$2.42BN/A-5.44120IBRXImmunityBio1.6341 of 5 stars$2.69+7.2%$12.19+353.1%-70.8%$2.30B$14.75M-2.92590Upcoming EarningsRXRXRecursion Pharmaceuticals2.2134 of 5 stars$5.63+4.1%$8.20+45.6%-34.1%$2.26B$58.49M-3.68400Upcoming EarningsGap UpTWSTTwist Bioscience3.6136 of 5 stars$36.94+6.9%$52.80+42.9%+18.0%$2.20B$330.19M-10.93990Upcoming EarningsPositive NewsDNLIDenali Therapeutics4.1558 of 5 stars$14.60+11.0%$37.57+157.3%-0.6%$2.12B$330.53M-5.29430Upcoming EarningsPositive NewsVCELVericel2.1572 of 5 stars$39.42-3.5%$60.86+54.4%-19.5%$1.98B$237.22M657.11300Upcoming EarningsPositive NewsBEAMBeam Therapeutics3.0729 of 5 stars$19.13+4.9%$49.45+158.5%-8.8%$1.91B$63.52M-10.87510Upcoming EarningsShort Interest ↑News CoverageTARSTarsus Pharmaceuticals2.0699 of 5 stars$49.44+1.9%$63.67+28.8%+54.8%$1.90B$182.95M-12.9850Earnings ReportUpcoming EarningsNews CoveragePositive NewsKYMRKymera Therapeutics2.0009 of 5 stars$28.80+6.0%$56.36+95.7%-4.7%$1.87B$47.07M-12.31170News Coverage Related Companies and Tools Related Companies Alvotech Alternatives Immunovant Alternatives ImmunityBio Alternatives Recursion Pharmaceuticals Alternatives Twist Bioscience Alternatives Denali Therapeutics Alternatives Vericel Alternatives Beam Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Kymera Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TALS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TALS Stock Free TALS Stock Alerts